$WMT $CVS: Infant ibuprofen recalled from Walmart, CVS, Family Dollar

Date: Friday, December 7th, 2018

Stock(s) mentioned: ,

Source: The Business Journals (https://www.bizjournals.com)

Summary: Walmart (NYSE:WMT) — “Equate” label, National Drug Code (NDC) 49035-125-23, lot numbers 00717009A, 00717015A and 00717024A; CVS (NYSE:CVS) …

Full article address: https://www.bizjournals.com/bizwomen/news/latest-news/2018/12/store-brand-infant-ibuprofen-recalled-from-walmart.html

Related News:

$WMT: Automation revolution… Walmart testing ‘Flippy’

$WMT $AMZN: Walmart’s Latest Acquisition Could Add $300 Million to Its Annual …

$WMT $FB $AMZN $GOOG: Peter Morici: Republicans must broaden their base or go the way of the Whigs

$WMT: A Look Back at Walmart’s Multibillion-Dollar Shopping Spree in 2018

$WMT $COST $TGT: Costco Earnings Preview: What to Watch

$AMZN $NKE $TGT $WMT: E-Commerce Companies Get Creative in Quest for ‘Last Mile’ Space

$GS $WMT $DIS: The Number One: How one 7-year-old boy earns as much as Wall Street legend Lloyd Blankfein

$WMT $AMZN: Bets Against Walmart’s Holiday Prospects Continue

$WMT $COST: Bets Against Walmart’s Holiday Prospects Continue

$AMZN $TGT $WMT $ETSY $EBAY: Online Holiday Sales Hit $78.1 Billion, Says Adobe Analytics

$NXTD $BBY $WMT $TGT: Widespread Popularity of Wearable Devices are Prompting the …

Latest News:

$DSW $CASY: 8 Stocks To Watch For December 11, 2018

$GNRC: Is Generac Holdings Inc. (GNRC) A Good Stock To Buy?

$DXC: DXC Technology Announces Additional Analytics Migration Factory …

$VZ $AMZN: 6 Most Important Things In Business Today

$GSK $BKNG: Is GlaxoSmithKline plc (GSK) A Good Stock To Buy?

$BP $BHP: Premium Pricing For Gulf Coast Oil Revives Interest In Eagle Ford …

$AMZN: New York Touted Real Estate, Eminent Domain in Bid for Amazon

$3998.HK $GOOS.T: Huawei Row Roasts Canada Goose

$SPX $COMP: Mark Hulbert: Brexit breakdown could be bullish for U.S. stocks

$DSW $ASNA: 8 Stocks To Watch For December 11, 2018

$PFE: Pfizer Slips Lower After JPMorgan Downgrade on Patent Cycle Concerns